Skip to main content

Table 1 Characteristics of studies included in the present meta-analysis

From: The effect of corticosteroids on mortality of patients with influenza pneumonia: a systematic review and meta-analysis

Study ID Study design RCT no. Population (corticosteroids/control) Type of influenza Type of corticosteroids Initial dose of corticosteroids (mean ± SD) Antiviral drug
Brun-Buisson [13] Retrospective analysis NR 83/125 H1N1 57.8% hydrocortisone
37.3% methylprednisolone
4.8% prednisone
328 ± 160 (equivalent hydrocortisone) NR
Cao [15] Retrospective study NR 204/84 H7N9 91.7% methylprednisolone
3.9% dexamethasone
2.5% hydrocortisone
2.0% others
81.1 ± 83.2 (equivalent methylprednisolone) Corticosteroids group: 201/204
Control group: 84/84
Diaz [12] Prospective observational multicenter study NR 136/236 H1N1 NR NR Corticosteroids group: 136/136
Control group: 236/236
Jung [16] Multicenter retrospective study NR 99/120 H1N1 NR NR Survivor: 130/141
Death: 68/78
Perez-Padilla [17] Retrospective study NR 7/11 H1N1 NR NR NR
Lee [18] Cohort study NR 264/817 H1N1 NR NR 151 in all the patients
Li [19] Case control NR 1055/1086 H1N1 89.0% methylprednisolone
8.1% dexamethasone
2.0% hydrocortisone
0.9% prednisolone
141.3 ± 142 (equivalent methylprednisolone) Corticosteroids: 1025/1055
Control group: 1022/1086
Moreno [20] Secondary analysis of a prospective cohort study NR 604/1242 Viral A/B/C 95.7% methylprednisolone;
3.8% prednisolone;
0.5% dexamethasone
A median (interquartile range) daily dose equivalent to 80 (60–120) mg of methylprednisolone NR
Rois [21] Multicenter prospective study NR 75/103 H1N1 NR NR Survivors: 91/93
Death: 82/85
Viasus [22] Observational, prospective cohort study NR 37/160 H1N1 NR NR Corticosteroids group: 8/37
Control group: 41/160
  1. NR not reported, SD standard deviation
\